Browsing by Subject "STAT3"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Astrocyte-mediated HIV-1 Tat neurotoxicity and its molecular mechanisms: astrocyte activation and impaired neurogenesis(2016-08-01) Fan, Yan; He, Johnny J.; Ghorpade, Anuja; Barber, Robert C.Human immunodeficiency virus type 1 (HIV-1) invasion of the central nervous system (CNS) often causes motor and cognitive dysfunction, which is termed HIV-associated neurocognitive disorders (HAND). Although the introduction of combination antiretroviral therapy (cART) has effectively suppressed viral replication, improved immune function and increased life expectancy among HIV-infected individuals, it has failed to provide complete protection from HAND or to reverse the disease. HIV-1 Tat protein is a major pathogenic factor in HAND. Studies including ours have demonstrated that Tat is taken up by HIV-1 uninfected brain cells and alters the function of these cells, especially astrocytes, neurons and neural progenitor cells. However, the underlying mechanisms are still unclear. There are two parts to my dissertation research. In the first part, we determined the roles of signal transducer and activator of transcription 3 (STAT3) in Tat-induced glial fibrillary acidic protein (GFAP) transactivation. Astrocytes, the most abundant cells in the brain, not only provide the scaffold support in the brain, but also are essential for maintaining the homeostasis of the brain. GFAP is the specific molecular marker for astrocytes, but it also modulates astrocyte function both physiologically and pathologically. In this study, we first showed that STAT3 expression and phosphorylation led to significant increases in GFAP transcription and protein expression. Then we determined that Tat expression was associated with increased STAT3 expression and phosphorylation in Tat-expressing astrocytes and HIV-infected astrocytes. In addition, we showed that GFAP, Egr-1 and p300 transcription all showed positive response to STAT3 and its phosphorylation. Moreover, knockdown of STAT3 resulted in significant decreases in Tat-induced GFAP and Egr-1 transcription and protein expression. Taken together, these findings show that STAT3 is involved in and acts upstream of Egr-1 and p300 in the Tat-induced GFAP transactivation cascade and suggest important roles of STAT3 in controlling astrocyte proliferation and activation in the HIV-infected CNS. In the second part of the dissertation research, we took advantage of the doxycyclineinducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) and determined the relationship between Tat expression and neurogenesis. Tat expression in astrocytes was associated with detection of fewer neuron progenitor cells (NPC), fewer immature neurons and fewer mature neurons in the dentate gyrus of the hippocampus of the mouse brain. In vitro NPC-derived neurosphere assays showed that Tat-containing conditioned media from astrocytes and recombinant Tat protein inhibited NPC proliferation and migration and altered NPC differentiation, while immunodepletion of Tat from Tat-containing conditioned media or heat inactivation of recombinant Tat abrogated those effects. Notch signaling downstream gene Hes1 promoter-driven luciferase reporter gene assay and Western blotting showed that recombinant Tat and Tat-containing conditioned media activated Hes1 transcription and protein expression, which were abrogated by Tat heat inactivation, immunodepletion, and cysteine mutation at position 30. Moreover, Notch signaling inhibitor DAPT significantly rescued Tat-impaired NPC differentiation in vitro and neurogenesis in vivo. Taken together, these results show that Tat adversely affects NPC and neurogenesis through Notch signaling and point to the potential of developing Notch signaling inhibitors as HAND therapeutics.Item TETRANDRINE INDUCED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) 3 CAUSES THE REDUCTION OF CELL SURVIVAL, PROLIFERATION, AND ANGIOGENESIS IN TNBC(2014-03) Gibbs, Lee D.; Chaudhary, Pankaj; Vishwanatha, JamboorNatural agents may be promising to combat aggressive behavior of the triple-negative breast cancer (TNBC). STAT3 is a protein that is highly expressed in breast cancer tissues compared to non-malignant breast tissues. Our objective for the present study is to analyze the anti-tumorogenic effects of a Chinese herbal drug, tetrandrine, in TNBC progression through inhibition of STAT3 phosphorylation. Purpose (a): The most successful therapies for breast cancer target the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her-2). Hormonal therapies are not useful in combating triple negative breast cancer (TNBC), which lacks these targeted hormonal receptors. In fact, some of these patients that undergo hormone deprivation and/or Herceptin therapy acquire resistance. The triple negative breast cancer (TNBC) phenotype, which lacks the presence of Her-2, ER, and PR are even more aggressive and resistant. Therefore, there is an urgent clinical need to identify novel agents that can kill tumor cells with no additional toxicity to normal cells and this would have great impact on treatment of such patients. Tetrandrine, a bis-benzylisoquinoline alkaloid isolated from the root of Stephania tetrandra, is a calcium channel blocker used in Chinese medicine for the treatment of silicosis and arthritis. Studies have shown that tetrandrine also has anti-tumor and anti-growth activities. Our objective is to study the effects of tetrandrine on STAT3 signaling that plays an important role in cell proliferation, survival, chemoresistance and angiogenesis. STAT3 protein is highly expressed in breast cancer tissues compared to non-malignant breast tissues. We hypothesize that tetrandrine treatment inhibits the phosphorylation of STAT3 and its associated downstream signaling lead to the reduction of cell survival, proliferation, and angiogenesis in TNBC cells. Methods (b): TNBC cell lines, MDA-MB-231 and HCC70, and non-tumorigenic epithelial cell line MCF-10A were cultured in ATCC recommended medium. MTT assays were carried out to determine the effect of tetrandrine on cell viability. Additionally, cells were subjected to various concentrations of tetrandrine and Western blotting was performed for analysis of protein expression and phosphorylation. Results (c): Our data indicate that tetrandrine selectively inhibits the growth of MDA-MB-231 and HCC70 cells compared to non-tumorigenic MCF-10A cells. In the MTT assay, Tetrandrine concentrations ranging from 0 to 40μM gradually decreased MDA-MB-231, HCC70 and MCF-10A cell viability, corresponding to IC50 values of 25, 20 and 75 μM (n = 8), respectively, after 48 hours of treatment. Our results show that tetrandrine inhibited the phosphorylation of STAT3 in a concentration dependent manner. Furthermore, the inhibition of STAT3 activation by tetrandrine led to the suppression of proteins involved in proliferation (cyclin D1), survival (Bcl-2, Bcl-xL, and Mcl-1), and angiogenesis (VEGF). This effect correlated with the inhibition of proliferation and apoptosis in TNBC cells. Conclusions (d): Our preliminary results suggest that tetrandrine inhibits the proliferation of TNBC cells through inhibition of constitutive STAT3 phosphorylation and it’s associated down stream signaling and has therapeutic potential in the treatment of TNBC.